7/18/2013

Navidea Biopharmaceuticals announced that an Australian clinical study will use its NAV4694 beta-amyloid imaging candidate instead of the Pittsburgh Compound B radiotracer. The Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Aging will use NAV4694 for its Alzheimer's disease and mild cognitive impairment research.

Related Summaries